Integrated Alzheimer’s Disease Rating Scale: Clinically meaningful change estimates

Alette M. Wessels¹ | Dorene M. Rentz²,³ | Michael Case¹ | Steve Lauzon¹ | John R. Sims¹

¹Eli Lilly and Company, Indianapolis, Indiana, USA
²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
³Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence
Alette M. Wessels, PhD, Eli Lilly and Company, 1 Lilly Corporate Center, Indianapolis, IN 46285, USA.
E-mail: wessels_lette_maria@lilly.com

Abstract
Introduction: The Integrated Alzheimer’s Disease Rating Scale (iADRS) has been used to detect differences in disease progression in early Alzheimer’s disease (AD). The objectives of this study were to enhance understanding of iADRS point changes within the context of clinical trials, and to establish a minimal clinically important difference (MCID) on the iADRS.

Methods: Data from AMARANTH and EXPEDITION3 were analyzed using various approaches, including anchor-based, distribution-based, regression analyses, and cumulative distribution function (CDF) plots. Three potential anchors were examined, including the Clinical Dementia Rating—Sum of Boxes, Mini-Mental State Examination, and Functional Activities Questionnaire. Triangulation of all results was used to determine the MCID for participants with mild cognitive impairment (MCI) due to AD and AD with mild dementia.

Results: All three anchors met criteria for “sufficiently associated” (|r| = 0.4–0.7). Cumulatively, results from anchor-based and distribution-based results converged to suggest an iADRS MCID of 5 points for MCI due to AD and 9 points for AD with mild dementia. Regression analyses and CDF plots supported these values.

Discussion: These findings suggest the iADRS can be used in clinical trials to detect a clinically meaningful outcome of AD progression.

KEYWORDS
Alzheimer’s disease, clinical meaningfulness, cognitive/functional composite endpoint, Integrated Alzheimer’s Disease Rating Scale, minimal clinically important change, minimal clinically important difference

1 | BACKGROUND

Alzheimer’s disease (AD) clinical trials are enrolling participants earlier on the disease continuum (i.e., patients with mild cognitive impairment [MCI] due to AD, or earlier). However, earlier intervention introduces a key challenge in clinical trials of AD: identifying a clinical outcome assessment (COA) to assess cognition and function that is sensitive, responsive, and able to detect clinically meaningful changes across the disease continuum (for a more detailed historical background, see Appendix A.1 in supporting information). Some commonly used COAs in clinical trials of MCI and/or AD with mild dementia include the Clinical Dementia Rating Scale–Sum of Boxes
Research in context

1. Systematic Review: The authors reviewed the literature using traditional (e.g., PubMed) sources and meeting abstracts and presentations. While previous studies have identified a minimal clinically important difference (MCID) for clinical outcome assessments used in clinical trials of Alzheimer’s disease (AD), no study has identified a MCID for the integrated Alzheimer’s Disease Rating Scale (iADRS).

2. Interpretation: Data from two large, randomized clinical trials and a combination of anchor, distribution, and supportive analyses were used to determine iADRS MCID. A five-point worsening on the iADRS for participants with mild cognitive impairment due to AD, and nine-point worsening for participants with mild AD dementia can be considered clinically meaningful. These results suggest the iADRS captures meaningful cognitive and functional changes.

3. Future directions: Clinical trials can use the iADRS and these established MCIDs to detect a clinically meaningful outcome of AD progression.

The iADRS has been validated, its statistical properties described, and it has been used, and is currently in use, as a clinical outcome measure in previous and ongoing phase 2 and 3 clinical trials in AD. Cumulatively, these data demonstrated the iADRS was effective in capturing disease progression from MCI throughout moderate AD, as well as treatment effects across the early disease spectrum. A more detailed description of the iADRS can be found in Appendix A. However, questions remain, including what magnitude of change on the iADRS represents a meaningful change in AD.

A minimal clinically important difference (MCID) is an individual, within-patient change in a COA, and is different than a between-group treatment effect. While between-group treatment effects are important clinical trial endpoints, used to determine the efficacy of an investigational treatment, the within-patient change is equally important because it measures the patient or physician perspective. Specifically, the MCID is a threshold for outcome scores (either patient-reported or physician-measured) over which a patient or physician would consider a given change in score to be meaningful and worthwhile. An MCID provides context around a patient’s progression and is therefore important to various stakeholders, including the patient, caregivers, and health-care decision makers (e.g., treating clinicians). In the case of iADRS, a MCID would provide details around an individual’s progression related to both cognition and function, over time.

The objectives of this study were to enhance understanding of iADRS point changes within the context of clinical trials, and to establish a MCID on the iADRS. As an increase in disease severity is associated with a faster cognitive and functional decline, the iADRS MCID will be calibrated by disease severity (i.e., MCI vs. AD with mild dementia).

2. METHODS

2.1. Study design

Data from two phase 3 trials, EXPEDITION3 and AMARANTH, were used (Table 1). Details on the population and study design from each trial have been described previously. Briefly, AMARANTH was a multicenter, randomized, double-blind, placebo-controlled study of lanabecestat in participants with early AD, defined as MCI due to AD or...
TABLE 1  Summary of data used in this retrospective analysis

|                      | AMARANTH (lanabecestat) | EXPEDITION3 (solanezumab) |
|----------------------|-------------------------|---------------------------|
| Design               | 104-week, phase 2/3 randomized, placebo-controlled trial | 80-week, phase 3, placebo-controlled trial |
| Indication           | Early AD (MCI due to AD and AD with mild dementia) | AD with mild dementia |
| Key inclusion criteria | Age | 55–85 | 55–90 |
|                      | AD diagnostic criteria | AD with mild dementia: meet NIA-AA criteria with CDR GS of 0.5 or 1, with memory box score of ≥0.5 | MCI due to AD: meet NIA-AA criteria with a CDR GS of 0.5, with memory box score of ≥0.5 |
|                      | MMSE score | 20–30 | 20–26 |
|                      | RBANS DMI | ≤85 | N/A |
| Amyloid positive     | CSF, florbetapir amyloid PET, or historical amyloid PET (florbetaben, florbetapir, flutemetamol, NAV-4694, PiB) | Florbetapir amyloid PET scan or Aβ1-42 measurements in CSF |

Abbreviations: Aβ, amyloid beta; AD, Alzheimer’s disease; CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; GS, Global Score; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; N/A, not applicable; NAV-4694, fluorine 18-labeled flutafuranol; NIA- AA, National Institute on Aging-Alzheimer’s Association; NINDS-ADRA, National Institute of Neurological Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association; PET, positron emission tomography; PiB, Pittsburgh compound B; RBANS DMI, Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index.

AD with mild dementia. EXPEDITION3 was a double-blind, placebo-controlled trial of solanezumab among participants who had AD with mild dementia.

Participants from the treatment and placebo arms of both trials were included in analyses if they had IADRS assessments at baseline and at endpoints of 52 and 78 weeks (AMARANTH) or at baseline and 52 and 80 weeks (EXPEDITION3), and a baseline plus endpoint assessment of at least one other cognitive or functional assessment—either the CDR-SB, the MMSE, or the FAQ. These assessments were chosen because they were considered potential anchors (described in Section 2.3), as these were the three COAs collected at baseline and endpoints in both trials.

2.2  | Clinical outcome assessments

For a scale-by-scale comparison of all clinical outcome assessments described in Section 2.2, see Table A.1 in supporting information.

2.2.1  | iADRS

The iADRS is a linear combination of its two components: the ADAS-Cog13 (range: 0–85; higher scores indicating greater deficit of global cognition) and the ADCS-iADL (range: 0–59; lower scores indicating greater impairment; items: 6a and 7–23). For more details on these individual components and iADRS development, see Appendix A.1. Because worse outcomes are indicated by higher scores on the ADAS-Cog13 and lower scores on the ADCS-iADL, the ADAS-Cog13 score is multiplied by −1 when calculating the iADRS score, such that lower iADRS scores indicate greater impairment. iADRS scores range from 0 to 144.

2.2.2  | CDR

The CDR is a clinician reported outcome measure designed as a staging instrument and is a semi-structured interview of participants and informants, after which a clinician rates the severity of symptoms across six domains of cognition and function. The CDR-SB is a continuous measure of dementia severity (range: 0–18; higher scores indicate greater impairment).

2.2.3  | MMSE

The MMSE is a brief instrument used to assess global cognitive function in participants (range: 0–30; lower scores indicate greater impairment). The instrument measures five areas: orientation, short term memory, attention, short term recall, and language.

2.2.4  | FAQ

The FAQ is an assessment used to measure complex functional activities of daily living, such as ability to shop, cook, and pay bills. The FAQ is an informant rating of performance changes in 10 complex activities of daily living (range: 0–30; higher scores indicate greater impairment).

2.3  | Anchor- and distribution-based approaches

The Food and Drug Administration (FDA) has recommended using primarily anchor-based methods, supplemented with empirical, distribution-based approaches and cumulative distribution function
TABLE 2  MCID estimates by disease severity over 1 year

|                        | MCI due to AD | AD with mild dementia | Moderate/severe AD dementia |
|------------------------|--------------|-----------------------|-----------------------------|
| CDR-SB†                | (Range: 0–18; higher = worse) | +1                     | +2                          | +2                          |
|                        |              |                       |                             |
| MMSE†                  | (Range: 0–30; lower = worse) | −1                     | −2                          | −3                          |
|                        |              |                       |                             |
| FAQ†                   | (Range: 0–30; higher = worse) | +3                     | +3                          | +3                          |

Abbreviations: AD, Alzheimer’s disease; CDR-SB, Clinical Dementia Rating Scale–Sum of Boxes; FAQ, Functional Activities Questionnaire; MCI, mild cognitive impairment; MCID, minimal clinically important difference; MMSE, Mini-Mental State Examination.

†Reference for CDR-SB MCID values is Lansdall et al.29.
†Reference for MMSE and FAQ MCID values is Andrews et al.4

(CDF) plots to estimate the MCID.18 Integration of MCID estimates from each of these approaches is known as triangulation.18

An anchor-based approach links change scores on an outcome measure to a meaningful external criterion (i.e., anchor) corresponding to participants’ or clinicians’ perception of meaningful change. The previously identified level of meaningful change on the anchor is then used to derive a threshold or range of score changes reflecting a clinically meaningful change on the new scale of interest, which in this case is the iADRS. Per guidance, an anchor should be: (1) plainly understood, (2) easier to interpret than the clinical outcome of interest, and (3) sufficiently associated with the target outcome.18 Based on previously established thresholds, a correlation (negative or positive) between 0.40 and 0.70 indicates two measures are “sufficiently associated.”28 suggesting appropriateness as an anchor. For these analyses, the CDR-SB, the MMSE, and the FAQ were each identified a priori as potential anchors, as they were available measures of cognition or function, are plainly understood in the context of cognition and/or function in AD clinical trials, and have established MCIDs. Furthermore, incorporating physician input, MCIDs have been established for the CDR-SB, MMSE, and FAQ (Table 2).4,29 allowing us to classify a change on the iADRS based on a previously established meaningful change on an existing scale. Multiple anchors were investigated per guidance suggesting multiple anchors are advantageous to refine and build confidence around a proposed threshold.20 For example, the iADRS was developed in an effort to improve upon existing COAs for AD clinical trials, given the limitations of existing COAs, described in Section 1. However, to acknowledge limitations to existing COAs, such as the CDR-SB, MMSE, and FAQ, is to acknowledge limitations of the anchors proposed here. Although each anchor may be limited in some way, if several imperfect anchors each correspond to the same proximate threshold or range of threshold values, it increases confidence in the proposed MCID.20

Distribution-based methods consider score changes in the context of variability and reliability of scores.19,20 Distribution-based parameters were selected based on previously published guidance.18 Distribution-based parameters are considered supportive evidence because they do not consider the patient’s or clinician’s perspective.18,20 Included distribution-based parameters were: effect size (ES), defined as the mean difference in score divided by the standard deviation (SD) of baseline scores; standardized response mean (SRM), defined as the mean difference in score divided by SD of the change; and half the SD (0.5 × SD) of baseline scores. ES and SRM are the most common responsiveness measures. For both, a value of ≥0.80 is considered large, 0.50 to 0.79 moderate, 0.20 to 0.49 small, and 0.00 to 0.19 very small.30

Per established guidance, the goal of triangulation is to identify a reasonable threshold value or range of values, using evidence from both anchor- and distribution-based approaches.18,20,31 Triangulation is not a formal analysis, but rather an expert review of anchor-based results combined with the distribution-based results and additional supportive analyses, including CDF plots. In this step, results from anchor- and distribution-based approaches are examined to determine whether there is convergence of results, pointing to a value or range of values that can be confidently identified as the within-patient MCID. While all results are considered, the relative importance of results varies during this step. Typically, anchor-based results are considered primary.18,20 Because multiple anchors are often explored simultaneously, they are based on previously established and clinically accepted thresholds, and they incorporate the patient perspective (i.e., are informed by patient, caregiver, or clinician judgment of disease status).18,20 Furthermore, results of various anchors are all considered, but the importance of anchors varies depending on the context in which the anchor may be most appropriate.20 In these analyses, the CDR-SB was identified a priori as the anchor of most relative importance out of the three considered anchors, given it measures both cognition and function, similar to the iADRS.

2.4  Statistical analysis

Baseline descriptive characteristics were calculated for each trial and reported by participants with MCI due to AD versus AD with mild dementia.

Pearson’s correlation coefficients between the iADRS and each potential anchor (CDR-SB, MMSE, and FAQ) were evaluated to determine appropriateness of each scale as an anchor. Mean iADRS change over 1 year was estimated for each cohort and each respective anchor threshold (e.g., 1-point worsening on CDR-SB in MCI over 1 year; Table 2). For EXPEDITION3, an 18-month iADRS mean change was
calculated for the CDR-SB anchor (the CDR-SB was not collected at 1 year). For each of the anchors and respective populations, ES, SRM, and 0.5 × SD baseline score were calculated.

Given the CDR-SB was considered a more important anchor than the MMSE or the FAQ, additional (supportive) analyses were performed with only this anchor. Analyses regressed change score on the iADRS versus CDR-SB unit changes. The regression model was fit without an intercept (i.e., the model assumed no change on CDR-SB equated to no change on iADRS). All participants with changes on both scales were included in the models. CDF plots provide an overall picture of change on an outcome measure against change on various anchor levels. CDF plots of change in iADRS from baseline to 52 weeks (AMARANTH) or 80 weeks (EXPEDITION3) by change in various CDR-SB anchor levels were created to determine the percentage of participants within each trial cohort that met the iADRS MCID criteria corresponding to each CDR-SB anchor level.

### RESULTS

Baseline characteristics were similar across both trials, including baseline CDR-SB, MMSE, and FAQ (Table 3).

At baseline, week 52 (AMARANTH), week 78 (AMARANTH), and week 80 (EXPEDITION3), the CDR-SB, MMSE, and FAQ all met criteria to be considered sufficiently associated with iADRS (Table A.2 in supporting information). Correlations were stronger as disease progressed.

The iADRS mean change varied slightly across anchors and by disease severity (Table 4). In AMARANTH, among participants with MCI due to AD who progressed +1 point/year on the CDR-SB, the mean (SD) change in iADRS was −5.5 (7.8; Table 4). Estimates were similar in AMARANTH and EXPEDITION3 for patients with AD with mild dementia (9.5 points/year or 12.2 points/1.5 years, respectively). Distribution-based results supported anchor-based results (Table 4).

Regession analyses examining the change in iADRS for every unit change in the CDR-SB from baseline to week 52 (AMARANTH) or week 80 (EXPEDITION3) aligned with anchor-based and distribution-based results (Table 5). A 1-point CDR-SB decline was associated with an approximate reduction of 4 points on the iADRS for participants with MCI due to AD (Table 5), slightly less than the anchor-based approach.

For participants with AD with mild dementia, a 2-point CDR-SB decline was associated with an approximate 10-point decline on the iADRS (Table 5), slightly more than the anchor-based approach.

Figure 1 shows the percentage of participants within each CDR-SB anchor level who met the established iADRS MCID within respective trial cohorts. In AMARANTH, among participants with MCI due to AD, approximately 50% of participants with a 1-point increase on the CDR-SB met the iADRS MCID of 5 points (Figure 1A). Among participants with mild AD with mild dementia, 50% of participants with a 2-point increase on the CDR-SB met the iADRS MCID of 9 points (Figure 1B). In EXPEDITION3, among participants with AD with mild dementia, approximately 60% of participants with a 2-point increase on the CDR-SB met the iADRS MCID of 9 points (Figure 1C).

As stated in Section 2.3, anchor-based results were generally weighted more heavily than distribution-based results, and results from the CDR-SB anchor were weighted more heavily than MMSE or FAQ. With this in mind, results from all approaches aligned to support an iADRS MCID of 5 points for participants with MCI due to AD and 9 points for participants with AD with mild dementia.

### DISCUSSION

Triangulation of various MCID thresholds obtained via anchor- and distribution-based methods indicated an iADRS MCID of 5 points for MCI due to AD, and 9 points for AD with mild dementia. Across two studies and all methods used, MCID estimates generally aligned. Additional regression analyses and CDF plots supported these iADRS MCIDs.

The iADRS MCIDs established here reflect a decline over time that, if met, is considered clinically meaningful. It is important to note a MCID is not the same as a potential treatment effect detected at a study endpoint. As stated previously, a MCID is an individual, within-patient change in a COA, indicative of a clinically meaningful change whereby the patient is expected to require either additional treatment or additional supportive care. This differs from a between-group
difference of 20%–30% is generally viewed as meaningful\(^32-34\). Thus, it is essential to understand the interrelationship of a MCID and a treatment effect when evaluating a MCID in the context of a disease-modifying intervention study. For example, if the iADRS is a COA used in a new clinical trial of MCI due to AD, one could infer the investigational treatment group would meet the MCID at 23.4 months (18\(\times\)30%). In other words, it takes the investigational treatment group 5.4 months longer to reach meaningful decline. As is the case with disease modifying treatments, the savings noted above will grow over time. Another way to think about this is to calculate the proportion of participants meeting the MCID in both study arms. The placebo-treated group is expected to show a greater proportion of participants meeting a meaningful decline, compared to participants in the treatment group. In other words, fewer participants in the treatment group will experience a decline considered meaningful.

The iADRS has a wide range of possible scores (0–144), with lower scores indicating a greater deficit in cognition and function. When used in the intended population, floor and ceiling effects are avoided, making it an appropriate outcome assessment for a broad range of disease severity or over longer investigation periods. In spite of the wide range, a baseline dynamic range (i.e., mean \(\pm\) 1 SD; capturing 68% of the distribution, assuming normality) has been estimated as 20 points for MCI and 24 to 28 points for AD with mild dementia.\(^7,12,13,35,36\) Thus, within the context of the dynamic ranges, a MCID of 5 points for MCI due to AD with mild dementia and 20 to 24 points for AD with mild dementia can be used to define meaningful decline in a patient population. The ADAS-Cog is a relatively narrow range of possible scores (0–70), with lower scores indicating a greater deficit in cognition and function. When used in the intended population, floor and ceiling effects are avoided, making it an appropriate outcome assessment for a broad range of disease severity or over longer investigation periods. In spite of the wide range, a baseline dynamic range (i.e., mean \(\pm\) 1 SD; capturing 68% of the distribution, assuming normality) has been estimated as 10 points for MCI and 14 to 17 points for AD with mild dementia. Thus, within the context of the dynamic ranges, a MCID of 5 points for MCI due to AD with mild dementia and 15 to 18 points for AD with mild dementia can be used to define meaningful decline in a patient population.

### Table 4

| AMARANTH MCI due to AD | AMARANTH AD with mild dementia | EXPEDITION3 AD with mild dementia |
|------------------------|-------------------------------|----------------------------------|
| CDR-SB (+1pt/yr)       | MMSE (+1pt/yr)                | FAQ (+3 pt/yr)                   |
| N 96                   | 74                             | 63                               |
| Anchor-based results   |                               |                                  |
| iADRS mean (SD) change | –5.5 (7.8)                    | –5.2 (7.9)                      |
| 95% CI                 | –7.1, –3.9                     | –7.2, –3.2                      |
| Range                  | –33, 10                        | –33, 10                          |

### Table 5

Regression analysis showing change in iADRS from baseline to 52, 78, or 80 weeks on change in CDR-SB score

| AMARANTH week 52 | AMARANTH week 78 | EXPEDITION3 week 80 |
|------------------|------------------|---------------------|
| MCI due to AD    | AD with mild dementia | MCI due to AD      |
| N 622            | 1062             | 360                 |
| Estimate         | –0.36\(^*\)(\(\Delta\) in CDR-SB) | –0.30\(^*\)(\(\Delta\) in CDR-SB) |
| 95% CI of slope  | (–0.45, –0.30)   | (–0.47, –0.30)      |

Abbreviations: AD, Alzheimer’s disease; CDR-SB, Clinical Dementia Rating Scale–Sum of Boxes; CI, confidence interval; ES, effect size; FAQ, Functional Activities Questionnaire; iADRS, Integrated Alzheimer’s Disease Rating Scale; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; mos, months; pt, patient; SD, standard deviation; SRM, standardized response mean; yr, year.
FIGURE 1  Cumulative distribution function curves of change in iADRS from baseline to 52 weeks (AMARANTH) by change in CDR-SB, for participants with MCI due to AD (A), AD with mild dementia (B), and 80 weeks (EXPEDITION3) by change in CDR-SB for participants with AD with mild dementia (C). AD, Alzheimer’s disease; CDR-SB, Clinical Dementia Rating–Sum of Boxes; iADRS, Integrated Alzheimer’s Disease Rating Scale; MCI, mild cognitive impairment; MCID, minimal clinically important difference

AD or 9 points for AD with mild dementia will be useful in interpreting clinical trial data, and treatment effects across the disease severity spectrum.

As discussed in Section 2.3, anchor-based results are considered primary per established guidance.\cite{18,20} It was important to consider multiple anchors, each chosen on "face value" because it measures a construct similar to the COA of interest (i.e., iADRS).\cite{18,20} While strong correlations between potential anchors and the COA of interest are anticipated, it must always be investigated to be certain of anchor appropriateness.\cite{18,20} These results showed the iADRS was sufficiently correlated with all three potential anchors, and the strength of each association increased over time, a previously demonstrated relationship\cite{37} indicating the anchor remains an appropriate choice as disease progresses. Within anchor-based results, the CDR-SB was considered the most appropriate anchor\cite{20} because, like the iADRS, it measures both cognition and function.\cite{6,9,24,25} Alternatively, the MMSE measures global cognition but not function, and the FAQ measures daily function but not cognition.\cite{6,26,27} That said, providing iADRS data against all three anchors was important because it allowed researchers and clinicians to make inferences about the performance of iADRS against well-established, well-accepted, and widely understood outcome measures.

CDF plots examined an overall picture of iADRS change over time for relevant CDR-SB anchor levels. This approach approximates the percentage of responders at other potential CDR-SB anchor levels and allows a visual comparison of separation between CDR-SB anchor levels, relative to the proposed iADRS MCID. For example, in AMARANTH, among participants with AD with mild dementia, 50% of participants with a 2-point worsening on the CDR-SB met the 9-point iADRS MCID. For participants with AD with mild dementia and a >2-point worsening on the CDR-SB, approximately 80% met the 9-point iADRS MCID, and 40% with a 1-point worsening on the CDR-SB met the 9-point iADRS MCID. Even among participants with AD with mild dementia who showed "improvement" on the CDR-SB, 16% met the 9-point iADRS MCID. These results show granularity of the iADRS versus the CDR-SB and support the usefulness of a wide score range that avoids floor and ceiling effects. The CDF plots support the iADRS detecting a clinically meaningful difference with more sensitivity than the CDR-SB. CDF plots support anchor- and distribution-based results, and a 9-point iADRS MCID for AD with mild dementia and 5 points for MCI due to AD.

Results from this study should be considered within the context of potential limitations. In Andrews et al.,\cite{4} the CDR-SB MCID estimate is based on a group mean (1.63 points for AD with mild dementia), whereas in analysis of participant-level data, CDR-SB scores occur on a continuous scale with 0.5-point increments. To allow differentiation from MCI (which had a MCID of 0.984), we analyzed our data based on a 2-point CDR-SB change for the AD with mild dementia group. Therefore, the established iADRS MCID for AD with mild dementia (9 points) may be slightly overestimated. Additionally, these (post hoc) analyses were limited to previously collected clinical trial measures. Some anchors (CDR and MMSE) were used in study screening or diagnostic process of the clinical trials; therefore, it cannot be ruled out that
results may be impacted by participant selection. A variable capturing "clinician-based judgment of meaningful decline" or an anchor reflecting patient/care partner input regarding "meaningfulness" was missing from existing clinical trial data. Finally, and as mentioned in Section 2.3, triangulation is not a formal statistical test, rather an interpretation of available evidence. In these analyses, we chose to use more heavily weight anchor-based analyses and the CDR-SB, and use distribution-based analyses, regression analyses, and CDF plots as supportive data. Different assumptions may have resulted in different MCID estimates.

Using data from two large, randomized clinical trials and a combination of anchor, distribution, and supportive analyses, we presented performance on the iADRS in relation to well-established, well-accepted, and widely understood outcome measures. These data will aid researchers and clinicians in the interpretation of iADRS scores and score changes in future clinical trials and existing data. Results show a 5-point worsening on the iADRS for participants with MCI due to AD and 9 points for participants with AD with mild dementia can be considered a clinically meaningful change. These findings suggest the iADRS is a valid cognitive and functional endpoint that can be used in clinical trials to detect a clinically meaningful outcome of AD progression.

ACKNOWLEDGMENTS
The authors thank Elizabeth (Nicki) Bush, Ellen Dennehy, and Laure Delbacque (Eli Lilly and Company) for review of this manuscript. Eli Lilly and Company contracted with Syneos Health for medical writing assistance from Andrea Metti, PhD, MPH and editorial support from Dana Schamberger, MA.

CONFLICTS OF INTEREST
Alette M. Wessels, Michael Case, Steve Lauzon, and John R. Sims are all employees and minor shareholders at Eli Lilly and Company. Dorene M. Rentz reports consulting relationships with Biogen IDEC and Digital Cognition Technologies; she also serves on the Scientific Advisory Board for Neurotrack.

FUNDING SOURCES
This study was funded by Eli Lilly and Company. The funder provided support in the form of salaries for authors AW, MC, SL, and JS. The funder had a role in study design, data collection, and analysis and interpretation of the data for AMARANTH and EXPEDITION3. For this post hoc analysis, the funder did not have a role in data analysis or interpretation, writing of the report, or decision to submit the article for publication.

REFERENCES
1. Liu-Seifert H, Siemers E, Price K, et al. Cognitive impairment precedes and predicts functional impairment in mild Alzheimer’s disease. J Alzheimers Dis 2015;47(1):205-214. https://doi.org/10.3233/jad-142508
2. Wessels AM, Dowsett SA, Sims R. Detecting treatment group differences in Alzheimer’s disease clinical trials: a comparison of Alzheimer’s Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB). J Prev Alzheimers Dis 2018;5(1):15-20. doi: 10.14283/jpad.2018.2
3. Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B. Suitability of the clinical dementia rating-sum of boxes as a single primary endpoint for Alzheimer’s disease trials. Alzheimers Dement 2011;7(6):602-610.e2. https://doi.org/10.1016/j.jalz.2011.10.005
4. Andrews JS, Desai U, Kirson NY, Zichlin M/L, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement (N Y) 2019;5:354-363. https://doi.org/10.1016/j.trci.2019.06.005
5. Liu-Seifert H, Andersen S, Case M, et al. Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat 2017;27(6):1104-1114. https://doi.org/10.1080/10543406.2017.1315819
6. McDougall F, Edgar C, Mertes M, et al. Psychometric properties of the clinical dementia rating - sum of boxes and other cognitive and functional outcomes in a prodromal Alzheimer’s disease population. J Prev Alzheimers Dis 2021;8(2):151-160. doi:10.14283/jpad.2020.73
7. Mintun MA, Lo AC, Evans CD, et al. Donanemab in early Alzheimer’s disease. N Engl J Med 2021;384(18):1691-1704. https://doi.org/10.1056/NEJMoa2107008
8. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356-1364.
9. L, B, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type 4. Evaluation of intervention. Ann Neurol 1992:31:242-249.
10. Wessels AM, Andersen SW, Dowsett SA, Siemers ER. The integrated Alzheimer’s Disease Rating Scale (iADRS) findings from the EXPEDITION3 trial. J Prev Alzheimers Dis 2018;5(2):134-136. doi:10.14283/jpad.2018.10
11. Wessels AM, Siemers ER, Yu P, et al. A combined measure of cognition and function for clinical trials: the integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alzheimers Dis 2015;2(4):227-241. doi: 10.14283/jpad.2015.82
12. Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018;378(4):321-330. https://doi.org/10.1056/NEJMoa1705971
13. Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and safety of abecacet for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol 2020;77(2):199-209. https://doi.org/10.1001/jamaneurol.2019.3988
14. A study of JNJ-63733657 in Participants with Early Alzheimer’s Disease (Autonomy). Clinicaltrials.gov identifi-
15. ADvance II Study: DBS-f in Patients with Mild Alzheimer’s Disease. Clinicaltrials.gov identifier: NCT03622905. Updated February 9, 2022. Accessed February 9, 2022. https://www.clinicaltrials.gov/ct2/show/NCT04619420?term=iADRS&draw=2&rank=1
16. Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer’s Disease (REFOCUS-ALZ). Clinicaltrials.gov identifier: NCT05026177. Updated January 14, 2022. Accessed February 9, 2022. https://www.clinicaltrials.gov/ct2/show/NCT05026177?term=iADRS&draw=3&rank=12
17. Simufilam 100 mg for Mild-to-Moderate Alzheimer’s Disease (RETHINK-ALZ). Clinicaltrials.gov identifier: NCT04994483. Updated February 8, 2022. Accessed February 9, 2022. https://www.clinicaltrials.gov/ct2/show/NCT04994483?term=iADRS&draw=2&rank=13
18. US Food and Drug Administration. Patient-Focused Drug Development Guidance Public Workshop. Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making. Accessed October 16, 2021: https://www.fda.gov/media/132505/download
19. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10(4):407-415. https://doi.org/10.1016/0197-2456(89)90005-6
20. Coon CD, Cook KF. Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res 2018;27(1):33-40. https://doi.org/10.1007/s11136-017-1616-3
21. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antideementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S13-S21.
22. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S33-S39.
23. Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer’s disease. J Am Geriatr Soc 2004;52(7):1070-1076. https://doi.org/10.1111/j.1532-5415.2004.52303.x
24. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412-2414. https://doi.org/10.1212/wnl.43.11.2412-a
25. O’Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s research consortium study. Arch Neurol 2008;65(8):1091-1095. https://doi.org/10.1001/archneur.65.8.1091
26. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-198. https://doi.org/10.1016/0022-3956(75)90026-6
27. Pfeffer RI, Kurosaki TT, Harrah CH Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37(3):323-329. https://doi.org/10.1093/geronj/37.3.323
28. Coon CD, Cappelleri JC. Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci 2016;50(1):22-29. https://doi.org/10.1177/2168479015622667
29. Lansdall CJ, Butler LM, Kerchner G, et al. Anchor- and distribution-based methods to establish clinically meaningful score changes on the clinical dementia rating scale - sum of boxes in patients with prodromal Alzheimer’s disease. J Prev Alzheimers Dis 2019;6(Suppl 1):199. https://www.ctad-alzheimer.com/files/files/CTAD%20OA%2C%20Vol%206%2C%20Suppl%201%2C%202019.pdf
30. Cohen J. Statistical power analysis for the behavioral sciences. Academic press; 2013.
31. Leidy NK, Wyrwich KW. Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD 2009;2(1):157-165. https://doi.org/10.1081/copd-200050508
32. Abushakra S, Porsteinsson A, Vellas B, et al. Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: The “APOE4 Gene-Dose Effect”. J Prev Alzheimers Dis 2016;3(4):219-228. doi:10.14283/jpad.2016.115
33. Insel PS, Weiner M, Mackin RS, et al. Determining clinically meaningful decline in preclinical Alzheimer’s disease. Neurology 2019;93(4):e322-e333. https://doi.org/10.1212/wnl.0000000000007831
34. Vellas B, Andreiu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol 2007;6(1):56-62. https://doi.org/10.1016/s1474-4422(06)70677-9
35. Mintun MA, Wessels AM, Sims JR. Donanemab in early Alzheimer’s disease. Reply. N Engl J Med 2021;385(7):667. https://doi.org/10.1056/NEJMc2109455
36. Tariot PN, Selzler KJ. Wessels A, et al. Subgroup populations in AMARANTH, a randomized phase 2/3 study in early Alzheimer’s disease with lanabecestat. 2019. Poster presented on 16 July 2019 at the Alzheimer’s Association International Conference. Los Angeles, CA. https://doi.org/10.1016/j.jalz.2019.06.4619
37. Liu-Seifert H, Siemens E, Selzler K, et al. Correlation between cognition and function across the spectrum of Alzheimer’s disease. J Prev Alzheimers Dis 2016;3(3):138-144. doi:10.14283/jpad.2016.99

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Wessels AM, Rentz DM, Case M, Lauzon S, Sims JR. Integrated Alzheimer’s Disease Rating Scale: Clinically meaningful change estimates. Alzheimer’s Dement. 2022;8:e12312. https://doi.org/10.1002/trc2.12312